Flavius Martin, MD, is joining Gilead Sciences as Executive Vice President, Research; also becoming a member of the company’s senior leadership team.
Dr. Martin brings significant experience overseeing industry-leading research, with particular expertise in oncology and inflammation. He joins Gilead from Amgen, Inc., where he most recently served as Vice President, Research Biology, leading discovery for Oncology, Inflammation and Cardiometabolic Research. He was also the site-head for Amgen South San Francisco.
Prior to Amgen, Dr. Martin worked as a scientist and leader at Genentech, Inc.
Dr. Martin received his MD at the University of Medicine and Pharmacy Timisoara, Romania. He completed his postdoctoral training at the University of Alabama at Birmingham in the Division of Developmental and Clinical Immunology. He has published numerous papers on the role of immune cells in driving inflammatory diseases and cancer, and holds a number of patents related to his discoveries.
Dr. Martin takes over the role from William (Bill) Lee, PhD, who is retiring after 30 years with Gilead. Since joining in 1991, he has overseen research programs across multiple therapeutic areas and led the advancement of numerous therapies from early-stage research into clinical developments.